AmpliPhi Biosciences Corp., a San Diego, California-based pharmaceutical development company that had been based in Richmond, has named a new chief executive officer.

Paul C. Grint was named CEO on May 31, succeeding M. Scott Salka, who resigned as CEO and as a director of the company but will serve as a consultant during a transition period.

AmpliPhi, which has its U.S. research laboratory in the Virginia Biotechnology Research Park in Richmond, is developing therapies to treat drug-resistant infections using bacteriophage-based technology.

Grint has served on the company’s board of directors since November 2015.

He previously served as president and CEO of Regulus Therapeutics Inc., a publicly traded biopharmaceutical company focused on the discovery and development of microRNA therapeutics. Grint received a medical degree from St. Bartholomew’s Hospital Medical College at the University of London.